F. Hoffmann-La Roche Ltd: [Ad hoc announcement pursuant to A

Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and are now in line with the prior year for

Related Keywords

Japan , Germany , United States , Argentina , Brazil , China , Russia , Canada , Switzerland , America , Swiss , Nathalie Meetz , Mabthera Rituxan , Gazyva Gazyvaro , Severin Schwan , Sileia Urech , Venclexta Venclyxto , September Roche , Actemra Roactemra , Patrick Barth , Karsten Kleine , International Region China , Genentech , Pathology Lab , World Health Organization , Diagnostics Division , International Region , Molecular Lab , Core Lab , Pharmaceuticals Division , Roche Group , European Medicines Agency , Pharmaceuticals Industry , Priority Review , Breakthrough Therapy Designation , Eastern Europe , Middle East , Latin America , North America , Breakthrough Therapy Designations , Delivery System , Therapy Designation , Roche Digital Pathology Open Environment , Accu Chek Guide , World Health Organization Model Lists , Essential Medicines , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Annual Report , Hoffmann , Oche , Announcement , Ursuant , Reports , Strong , Growth , First , Line , Months , Outlook , 021 , Aised ,